ZALTENIBART
UNII 0SOY20O318

Substance Identification & Data

This profile provides standardized clinical and technical data for Zaltenibart, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 0SOY20O318.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2527079-60-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

0SOY20O318

CAS Registry Number

2527079-60-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

ZALTENIBART

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C207015

National Cancer Institute reference terminology for clinical and research data.

INN ID

12858

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

MN-81

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Zaltenibart. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

ZALTENIBART

Common Names & Synonyms

H-GAMMA4 HEAVY CHAIN (1-440) (VH MUSMUS/HOMSAP (MUS MUSCULUS IGHV1-9*01 (79.6%) -(IGHD) -IGHJ3*01 (90.9%) A128>S (113)/HOMO SAPIENS IGHV1-46*01 (79.6%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT (8.8.6) (26-33.51-58.97-102)) (1-113)-HOMO SAPIENS IGHG4*01, NG4M(A) CH2 L92, G4V5 H P10, G4V24 CH3 L107, S114 (CH1 (114-211), HINGE 1-12 S10>P (221) (212-223), CH2 L92 (302) (224-333), CH3 M107>L (421), N114>S (427) (334-438), CHS (439-440)) (114-440)), (127-219')-DISULFIDE WITH L-KAPPA LIGHT CHAIN (1'-219') (V-KAPPA (HOMO SAPIENS IGKV4-1*01 (91.1%) -IGKJ1*01 (100%), CDR-IMGT (12.3.8) (27'-38'.56'-58'.95'-102')) (1'-112') -HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (158'), V101 (196') (113'-219')); DIMER (219-219'':222-222'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-DG44, GLYCOFORM ALFA

HUMANIZED IMMUNOGLOBULIN G4 MONOCLONAL ANTIBODY DIRECTED AGAINST MANNAN-BINDING LECTIN-ASSOCIATED SERINE PROTEASE-3 (MASP-3)

IMMUNOGLOBULIN G4 (221-PROLINE,421-LEUCINE,427-SERINE), ANTI-(HUMAN SERINE PROTEINASE MASP3) (HUMAN-MUS MUSCULUS MONOCLONAL OMS906 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL OMS906 .KAPPA.-CHAIN, DIMER

IMMUNOGLOBULIN G4-KAPPA, ANTI-(HOMO SAPIENS MASP3 (MANNAN-BINDING LECTIN-ASSOCIATED SERINE PROTEASE-3))

RECOMBINANT HUMANISED IGG4 KAPPA ANTI-(MASP 3) DISULFIDE MONOCLONAL ANTIBODY OMS906

ZALTENIBART [INN]

ZALTENIBART [USAN]